Wikisage, the free encyclopedia of the second generation, is digital heritage

Lamictal XR: Difference between revisions

From Wikisage
Jump to navigation Jump to search
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
lamotrigine slow release<ref>https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lamictal_XR/pdf/LAMICTAL-XR-PI-MG.PDF</ref>
[[lamotrigine]] slow release<ref>https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lamictal_XR/pdf/LAMICTAL-XR-PI-MG.PDF</ref>
risk increases conmmitant administration with valproate
risk increases conmmitant administration with valproate


Line 6: Line 6:


this presentation is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older.
this presentation is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older.
<references/>
 
 
==Links==
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf
 
{{wikidata|Q410346}}
lamotrigine
{{refs}}

Latest revision as of 23:26, 29 January 2023

lamotrigine slow release[1] risk increases conmmitant administration with valproate

Stevens Johnson has been observed in 8 per 1000 cases


this presentation is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older.


Links

http://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf

Q410346 at Wikidata  Interwiki via Wikidata

lamotrigine

References

References: